Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,789,140.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $504.12, for a total value of $4,789,140.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $163,558,205.16. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

United Therapeutics Stock Down 0.5%

NASDAQ:UTHR traded down $2.35 during midday trading on Tuesday, reaching $500.35. The stock had a trading volume of 1,326,936 shares, compared to its average volume of 496,432. The stock has a market cap of $21.46 billion, a P/E ratio of 17.90, a P/E/G ratio of 2.49 and a beta of 0.56. United Therapeutics Corporation has a 12-month low of $397.00 and a 12-month high of $609.35. The firm has a fifty day simple moving average of $520.02 and a two-hundred day simple moving average of $540.96.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter last year, the business earned $6.41 EPS. The business’s revenue was down 1.9% on a year-over-year basis. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on UTHR. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Bank of America decreased their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Finally, Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently bought and sold shares of UTHR. BlackRock Inc. bought a new stake in United Therapeutics in the second quarter valued at about $2,868,735,000. Janus Henderson Group PLC lifted its holdings in United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after buying an additional 70,829 shares during the last quarter. Jupiter Topco LLC acquired a new position in shares of United Therapeutics in the 2nd quarter worth approximately $450,140,000. Norges Bank acquired a new position in shares of United Therapeutics in the 4th quarter worth approximately $293,418,000. Finally, Swedbank AB increased its holdings in shares of United Therapeutics by 0.7% in the 1st quarter. Swedbank AB now owns 327,122 shares of the biotechnology company’s stock valued at $193,977,000 after acquiring an additional 2,350 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.